Outlook Therapeutics to Host Virtual Clinical Day on May 20, 2021
During the Virtual Clinical Day,
Key opinion leaders will also join the management team to discuss Outlook Therapeutics’ current clinical program and strategy, as well as the market need for a responsibly priced, ophthalmic formulation of bevacizumab approved by the
Mark Humayun, MD, PhD, Medical Advisor to Outlook Therapeutics; Ophthalmologist, Engineer, Inventor; National Medal of Technology and Innovation awarded by President Barack Obama, 2016; Top 1% Ophthalmologists ( U.S. News & World Report); Member, U.S.National Academics of Medicine and Engineering; Pyron Award, American Society of Retina Specialists; Past President, American Society of Retina Specialists; Co-inventor of Argus II, which offers functional sight to patients with complete retinal blindness Firas M. Rahhal, MD, Senior Partner, Retina-Vitreous Associates Medical Groupin Los Angelesand Associate Clinical Professor of Ophthalmology at the UCLA Geffen School of Medicine
Interested participants and investors may dial into the event using (877) 407-9708 (domestic) or (201) 689-8259 (international), or can access the live video webcast and accompanying slide presentation on the Events page of the Investors section of the
About ONS-5010 / LYTENAVA™ (bevacizumab-vikg)
ONS-5010 is an investigational ophthalmic formulation of bevacizumab under development to be administered as an intravitreal injection for the treatment of wet AMD and other retinal diseases. Because no currently approved ophthalmic formulations of bevacizumab are available, clinicians wishing to treat retinal patients with bevacizumab have had to use unapproved repackaged IV bevacizumab provided by compounding pharmacists, products that have known risks of contamination and inconsistent potency and availability. If approved, ONS-5010 will reduce the need for use of unapproved repackaged IV bevacizumab from compounding pharmacists for retinal disease.
ONS-5010 is a full-length, humanized anti-VEGF (Vascular Endothelial Growth Factor) recombinant monoclonal antibody (mAb) that inhibits VEGF and associated angiogenic activity. VEGF is a protein that promotes the growth of new abnormal blood vessels. With wet AMD, abnormally high levels of VEGF are secreted in the eye and lead to loss of vision. Anti-VEGF injection therapy blocks this growth. Since the advent of anti-VEGF therapy, it has become the standard-of-care treatment option within the retina community globally.
Assistant Vice President
Chief Executive Officer
Source: Outlook Therapeutics, Inc.